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Abstract
Background: Acute bronchitis is one of the most prevalent respiratory infections in primary care, and in more than
90% of the cases antibiotics are prescribed, mainly when purulent expectoration is present. However, this process is
usually viral in origin and the benefits of antibiotic treatment are marginal. On the other hand, in recent years
bronchitis has been considered more as an inflammatory than an infectious process. Thus, the aim of this study is
to evaluate the clinical effectiveness of a schedule of an oral anti-inflammatory compared with an antibiotic
regimen and another group assigned to receive a placebo.
Methods and design: A total of 420 patients from 15 to 70 years of age with no associated comorbidity,
presenting respiratory tract infection of at least one week of evolution, with cough as the predominant symptom,
the presence of purulent expectoration and at least one other symptom of the respiratory tract (dyspnoea,
wheezing, chest discomfort or pain), with no alternative explanation such as pneumonia, will be included in a
prospective, randomised and controlled, clinical trial with placebo. The patients will be randomised to receive one
of three treatments: ibuprofen, amoxycillin and clavulanic acid or placebo for 10 days. The main outcome measure
is the number of days with frequent cough defined by the symptom diary with a score of 1 or more.
Discussion: This trial is designed to evaluate the number of days with frequent cough with anti-inflammatory
treatment compared with antimicrobial treatment and placebo in previously healthy patients with a clinical picture
of acute bronchitis and purulent expectoration. It is hypothesized that anti-inflammatory treatment is more
effective than antibiotic treatment to reduce cough, which is the most disturbing symptom for patients with this
infection.
Trial registrationISRCTN07852892
Background
Acute bronchitis is a clinical term which implies a self-
limiting infection of the large airways and is character-
ized by clinical manifestations of cough without pneu-
monia [1]. This process affects approximately 5% of
adults annually with a greater incidence in the winter. It
accounts for 9.4% of the infections attended by family
physicians [2]. Acute bronchitis is mainly a viral infec-
tion [3,4]. The role of bacteria in this infection con-
tinues to be controversial since bronchial biopsies have
never demonstrated bacterial invasion. In some cases
atypical germs may be involved including Bordetella per-
tussis, Chlamydophila pneumoniae and Mycoplasma
pneumonia [1,5].
It is thought that acute bronchitis reflects an inflamma-
tory response to infections of the epithelium of the
bronchi. Microscopic examination demonstrates a thick-
ening of the bronchial and tracheal mucosa corresponding
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sistent with publications of proximal lower airway inflam-
mation observed with positron emission tomography [6].
During the first days of infection, the symptoms of upper
respiratory infections cannot be clinically distinguished
from the symptoms of acute bronchitis. However, in acute
bronchitis cough lasts more than five days and during this
prolonged period of symptoms, the results of functional
respiratory tests are usually abnormal. Forty per cent of
the patients present significant reductions in forced espira-
tory volume in the first second (FEV1) with values of less
than 80% over the theoretical value, or bronchial hyper-
reactivity with improvement during the following 5-6
weeks [7]. Cough may persist from 10 to 20 days in acute
bronchitis, but it may sometimes last up to 4 weeks or
more. In a recent study on the efficacy of the acellular per-
tussis vaccine including 2,781 healthy adults, the mean
duration of cough in acute bronchitis by all causes was 18
days, with a median of 24 days [5]. Moreover, almost half
of the patients with acute bronchitis report the production
of purulent expectoration. Peroxidase released by the leu-
kocytes in sputum causes the colour changes; hence, col-
our alone should not be considered indicative of bacterial
infection [8]. Indeed, in healthy adults, the positive predic-
tive value of purulent sputum for the presence of alveolar
disease is low, being of approximately 10% [9].
Bronchitis has shown to reduce the quality of life of
patients. One study on the quality of life of patients
with infections of the upper respiratory tract, some of
which were labelled acute bronchitis, showed a reduc-
tion in seven subscales of the 36-item Short-Form Gen-
eral Health Survey, including vital and social function,
although this decrease was transitory [10]. Furthermore,
up to twenty per cent of the patients return to their
physician within the first month for the persistence of
symptoms [1].
Previous research
There is clear evidence that antibiotics should not be
recommended in non-complicated acute bronchitis.
However, their use on behalf of primary care physicians
in Spain is greater than 80% [11,12]. Similar percentages
have been reported by primary care practitioners in Uni-
ted States and other countries [13,14]. Systematic ana-
lyses of clinical trials suggest that antibiotics may achieve
a reduction, albeit only marginal, in the duration of the
symptoms. Specifically, a meta-analysis of 8 clinical trials
showed that the symptoms reduced a few hours with the
use of doxycycline, erythromycin or trimethoprim/sul-
phamethoxazole [15]. The results were statistically signif-
icant but clinically trivial. The results of a randomized,
double-blind study in which a course of azithromycin
during 5 days in 112 patients was compared with vitamin
C in 108 patients published after this meta-analysis did
not show any difference between groups in the quality of
life at 7 days (main outcome variable) or in the propor-
tion of patients who had to return to work, school or
normal activities at home at days 3 or 7 [16]. A review of
the Cochrane Library including 9 randomized, controlled,
clinical trials of antibiotic agents (including three clinical
trials not included in the previous review) also showed a
significant, albeit lower, reduction in the duration of
cough, of only 0.6 hours [17]. A non-significant reduction
in the number of days of feeling badly and a non-signifi-
cant increase in the number of adverse effects attributed
to the antibiotic therapy (relative risk of adverse effects:
1.22; CI95%: 0.94 to 1.58) were also found [17]. At this
point, the study by Stott et al. is of note in which only
patients with acute bronchitis with purulent expectora-
tion were included and in which no statistically signifi-
cant differences were observed in the resolution of cough
between the group treated with antibiotics and those
assigned to the control group [18]. Thus, Spanish pri-
mary care physicians have the perception that the pre-
sence of purulent expectoration in the course of acute
bronchitis is suggestive of bacterial superinfection, very
probably due to the fact that purulent expectoration is a
criterion of antibiotic therapy in patients with other
lower respiratory tract infections such as acute exacerba-
tions of chronic obstructive pulmonary disease [19].
Indeed, in a questionnaire given to more than 1,000 pri-
mary care physicians, more than 90% responded that
they would treat a 30-year-old patient with associated
comorbidity presenting a non-pneumonic respiratory
infection with sputum purulence with antibiotics [20].
In recent years the idea that acute bronchitis is more
an inflammatory than infectious process has begun to
take shape [1,21]. Thus, non-steroidal anti-inflammatory
drugs have shown to be effective in reducing the dura-
tion and the intensity of cough in patients with bronchi-
tis in observational studies and they are therefore
recommended in the guidelines of clinical practice.
However, their effectiveness has not been observed in
clinical trials. To date, no study has been published
comparing the role of anti-inflammatory drugs with
antibiotics. We therefore designed this clinical trial with
the aim of determining the effectiveness of ibuprofen
(most frequently prescribed anti-inflammatory drug in
Spain) compared with the combination of amoxicillin
and clavulanic acid (antibiotic most often prescribed by
Spanish primary care physicians) and also compared
with a placebo groups of healthy adult patients with
acute bronchitis and purulent expectoration.
Objectives
The aim of the study is to evaluate the number of days of
frequent cough (defined by the symptom diary with a
score of 1 or more) in the three treatment arms (oral
Llor et al. BMC Pulmonary Medicine 2011, 11:38
http://www.biomedcentral.com/1471-2466/11/38
Page 2 of 6anti-inflammatory, antibiotic or placebo) taken during 10
days. The secondary objectives are to evaluate the efficacy
on the second visit, evaluate the speed of action in the
resolution of the symptoms of acute bronchitis in the
three treatment arms, assess the relationship between C-
reactive protein concentrations and the resolution of the
symptoms in each treatment arm and evaluate the sec-
ondary effects and adverse reactions in the three treat-
ment arms of the study.
Methods
Design of the study
The study entails a 3-armed randomized clinical trial
performed in Catalonia, Spain. The medical Ethics Com-
mittee Fundació d’Investigació en Atenció Primària has
approved the study design, the protocols, information
letters to the patients and the informed consent form.
The study has obtained a grant from the Fondo de
Investigación Sanitaria of the Ministry of Health and
Consumption in the announcement of independent
investigation and has been approved by the Spanish
Agency of Medication and Healthcare Products.
Recruitment
Patients from 18 to 70 years of age without associated
respiratory comorbidity or immunosuppression, present-
ing respiratory infection of at least one week of evolu-
tion, with cough as the predominant symptoms and the
presence of purulent expectoration of at least one week
of duration and at least one other respiratory tract
symptom such as dyspnoea, wheezing, chest discomfort
or pain, with no alternative explanation such as pneu-
monic condensation, will be recruited from several
healthcare centres in Catalonia.
Exclusion criteria will be: patients less than 18 and older
than 70 years of age, the presence of radiological signs of
pneumonia, signs of severe infection (confusion, tachyp-
noea > 25 respirations per minute of tachycardia > 120
beats per minute), history of digestive haemorrhage or
intolerance to anti-inflammatory treatment, hypersensitiv-
ity to b-lactams or intolerance toc l a v u l a n i ca c i do rl a c -
tose, pregnancy, lactation and women of fertile age not
using contraceptive measures, antibiotic, anti-inflamma-
tory or corticosteroid use in the previous two weeks, asso-
ciated comorbidity (bronchial asthma, chronic obstructive
pulmonary disease, moderate-severe heart failure, demen-
tia, stroke, immunosuppression or the use of immunosup-
pressive drugs), emergency situation, institutionalization in
a residence, and/or subjects unable to personally provide
informed consent.
Randomization
The patients will be randomized with simple random
numbers to one of the three following treatment arms:
￿ Ibuprofen 600 mg/8 hours, during 10 days, taken
after meals.
￿ Amoxicillin plus clavulanic acid 500-125 mg/8
hours, during 10 days, taken after meals.
￿ Placebo, one tablet every 8 hours, during 10 days,
taken after meals.
The use of acetaminophen will be allowed in cases of
fever or pain, as will short life b-adrenergics or anticho-
linergics in cases of bronchospasm and mucolytics, anti-
cough and any medication that the patient may be tak-
ing for chronic disease and which has been initiated one
month prior to inclusion in the study except for antibio-
tics, inhaled, oral or parenteral corticoids or non-steroi-
dal anti-inflammatory drugs. In cases of clinical
deterioration, the medical investigator will evaluate the
need for hospitalisation and in the case of outpatient
treatment, high dose antibiotic treatment with amoxycil-
lin and clavulanic acid will be administered.
The patient will have to return all the medication
samples not taken to the investigator. If the left over
medication is not returned, adherence will be assessed
as insufficient and the case will be classified as abandon-
ment. Prescription adherence will be evaluated and will
be considered satisfactory if the patient has taken at
least 80% of the dose foreseen.
Measurements
The main outcome variable considered in this study is the
number of days with frequent cough. Secondary result
variables considered will be the efficacy of the treatment,
the time of symptom resolution, the reduction in the total
daily score of the symptom diary and the secondary effects
and adverse reactions which may present with the three
treatment arms. With regard to efficacy, three outcomes
will be distinguished: cure, defined as the disappearance of
the acute signs and symptoms related to the infection
(complete return to the previous situation of stability),
improvement, defined as the non-complete resolution of
the symptoms and failure, with an insufficient reduction in
the signs and symptoms of infection.
The following variables will be taken into account in
this study:
￿ Age, sex, presence of smoking, packets-year, pre-
sence of diabetes, heart failure, ischemic heart disease.
￿ Treatment administered by the physician: mucolytics
or expectorants, antihistaminics, bronchodilatadors, anti-
tussives, analgesics.
￿ Colour of the sputum: yellowish or yellowish-green.
￿ Clinical manifestations of the patient: dyspnoea,
wheezing on auscultation, chest discomfort, chest pain,
pain (>38°C).
￿ Concentration of C-reactive protein in capillary
blood, with quantitative apparatus (QuikRead of Orion
Diagnostica).
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any complication such as pulmonary condensation (in
which case, the patient will be excluded from the study);
or negative.
￿ Symptom diary: Five symptoms will be evaluated: dis-
ease severity, day-time cough, night-time cough, limitation
in daily activity and febrile sensation. Each of the symp-
toms will be scored from 0 to 4. It will be recommended
that the patient fill out this diary before going to bed. This
symptom diary has previously been used in other studies
[22].
￿ Secondary effects and adverse reaction which might
appear in the three treatment arms.
Four visits have been established in this study (Table 1).
On the baseline visit the study will be explained to the
patient and informed consent will be requested. The
scheme of the investigation will also be explained to the
patient. The patients will be randomized to any of the
three treatment groups and the medication will be given
with 33 tablets (three extra tablets are given in case of
loss). On this visit the C-reactive protein will be deter-
m i n e da n dac h e s tX - r a yw i l lb ep e r f o r m e di nc a s e sw i t h
suspected pneumonia. In addition, a symptom diary will
be given as will an explanation as to how to fill it in.
The first follow up visit will be programmed at 2-4
d a y s .O nt h i sv i s i tt h ep r e s e n c eo fs i d ee f f e c t sa n d
adverse reactions will be assessed. In addition, the clini-
cal evolution of the symptoms and signs will be evalu-
a t e da n d ,i nt h ec a s eo fw o r s e n i n go ft h es y m p t o m s ,
hospital referral or the administration of antibiotic treat-
ment will be considered. The second follow up visit will
be made at 11-13 days with a review of adherence to
the study drug and an evaluation of the presence of side
effects and adverse reactions. The patients classified as
clinical failure will be managed as in the previous visit.
The symptom diary will be collected and another diary
will be given if the patient continues to have symptoma-
tology. Patients classified as cure will finish the study on
this visit and those classified as improvement will be
given an appointment at 30 days of having initiated the
treatment with a new diary, considering this as the last
visit of the study.
The data of the study will be collected on a data col-
lection sheet, a one-sided form sheet which the partici-
pating investigator will have identified with the number
of randomization indicated on this sheet, on the symp-
tom sheet given to the patient and on the medication
bottle given to the patient. The randomization codes
will be kept by the Pharmacy Unit of the Hospital Vall
d’Hebron of Barcelona.
Sample size
We will accept a null hypothesis if the number of days of
frequent cough in the anti-inflammatory arm is the same
or ± 2 days as that observed in the other two treatment
arms (placebo and antibiotic treatment). Based on the lit-
erature, the standard deviation of the duration of frequent
cough is 5.5 days in patients with chronic bronchitis and
purulent sputum. For an a: 0.05 and a b: 0.2 and accepting
possible losses of 15%, we calculate that the sample size
should be of 140 patients per group (total of 420 patients).
Analysis
Intention-to-treat statistical analyses will be performed.
To analyse the time until cure of the different symptoms
and for the main result variable (days from the onset of
the picture until the patient scores a maximum of 1 in
the box related to cough in the symptom diary) survival
analysis will be carried out using the Kaplan-Meier
method. Comparison between the three survival curves
will be undertaken using the log-rank test. In addition,
bivariate analysis will be peformed with comparison of
proportions using the chi-square test to evaluate sec-
ondary variables of the study and variance analysis to
assess the relationship between quantitative variables for
both independent and paired data.
Ethical considerations
Approval has been obtained from the Ethical Committee
of Investigation in Primary Care (Fundació d’Investigació
Table 1 Study measurements
Baseline 2-4 days 11-13 days 30 days
Randomization x
C-reactive protein x
Chest X-ray x
Hand-out of the symptom diary x x (1)
Side effects and adverse reactions assessment x x x (1)
Evaluation of clinical evolution x x x (1)
Review of adherence x
Collection of symptom diary x x (2)
(1) If the patient continues to have symptomatology on day 11-13
(2) If the patient has been given the second diary symptom
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t e r e di na ni n t e r n a t i o n a ld a tabase (ISRCTN07852892).
Informed consent will be requested from all the partici-
pants in the study, respecting subject autonomy in their
decision. To achieve this, the medical investigator will
read the informed consent sheet to the patients and clar-
ify any doubt which might arise during the reading.
Thereafter, patient comprehension of the information
will be determined and, in the case of acceptation to par-
ticipate, the patient will be asked to sign the form. This
s t u d yd o e sn o tr e q u i r et h eu s eo fu n u s u a l ,a d d i t i o n a l
tests: only a chest X-ray will be undertaken to rule out a
pneumonic process and determination of the C-reactive
protein during the visit to know the severity of the infec-
tion, being a test that is total justified in this project.
From an ethical point of view, this is to certify that the
objective of this study is important and relevant for pri-
mary care, the power of the study may be considered as
reasonable, this is an original study, the risks which the
participants may incur justify the investigation being car-
ried out with a totally favourable benefit/risk quotient, and
we ensure the external validity of the study to the primary
care reality, with the inclusion and exclusion criteria
described. Vulnerable populations will not participate in
this study and neither will economic compensation be
given to patients for their participation. The investigators
are free to publish the results of this study, regardless of
the results obtained. We guarantee the anonymity and
confidentiality of the data, the protocol of the study will
safeguard that in results of the study all the participants
and their individual results will be taken into account. The
privacy of the participants will be protected and with the
randomised design of the study the subjects will be equally
invited to participate and we consider that the possible
benefits or adverse effects of the investigation will be
equally shared among all the participants.
Discussion
This article presents a detailed description of a rando-
mized clinical trial protocol study designed to explore
the effectiveness of ibuprofen to alleviate the cough pre-
sent in patients with acute bronchitis and purulent
expectoration compared with a broad-spectrum antibio-
tic and placebo. The trial proposed is sufficiently pow-
ered and, to the best of our knowledge, the first to allow
conclusions on the effect of an anti-inflammatory drug
and compare it with antibiotic therapy. Acute bronchitis
is a very prevalent disease and is one of the most fre-
quent causes of medical visits in primary care. Patients
often return to their physician or seek other medical
help because the symptoms of the disease may persist
f o rt w oo rt h r e ew e e k s ,m a i n l yc o u g h ,w h i c hm a yb e
very bothersome for the patient. Many physicians may
not give antibiotics on the first visit and may prescribe
mucolytics and/or antitussives. However, since health-
care professionals often do not explain the natural evo-
lution of bronchitis and since the patients are often told
that these drugs will cure the patient, the patient returns
with the same demand. Butler et al. reported similar
results, with only 5% of the professionals explaining to
their patients with bronchitis that the cough would last
at least two weeks [23]. When the patient returns and
particularly when the patient presents purulent mucous
expectoration, the physician is more likely to prescribe
an antibiotic [24]. Thus, only patients with acute bron-
chitis and yellowish-green expectoration will be included
in this clinical trial.
This study will involve the use of drugs which have
been in the pharmaceutical market for more than 20
years. Moreover, we will take into account the most
commonly used drugs in Spain for each of the two
pharmacological groups: ibuprofen among the anti-
inflammatory drugs and amoxicillin and clavulanic acid
a st h ea n t i b i o t i cu s e di nl o w e rr e s p i r a t o r yt r a c ti n f e c -
tions. This is, therefore, a phase IV clinical trial and, as
such, we believe that important adverse effects will not
be produced. This trial will deliver important findings
on the effects of these drugs and the results will provide
information on which of the two drugs produces the
best results to alleviate cough using the symptom diary
which the patients will be trained to fill in.
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